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Abstract
Background: The target delivery channel of RTS,S candidate malaria vaccines in malaria-endemic countries in Africa is the
World Health Organisation Expanded Program on Immunization. As an Adjuvant System, age de-escalation and schedule
selection step, this study assessed 3 schedules of RTS,S/AS01E and RTS,S/AS02D in infants and young children 5–17 months
of age in Ghana.
Methodology: A Phase II, partially-blind randomized controlled study (blind to vaccine, not to schedule), of 19 months
duration was conducted in two (2) centres in Ghana between August 2006 and May 2008. Subjects were allocated randomly
(1:1:1:1:1:1) to one of six study groups at each study site, each defining which vaccine should be given and by which schedule
(0,1-, 0,1,2- or 0,1,7-months). For the 0,1,2-month schedule participants received RTS,S/AS01E or rabies vaccine at one center
and RTS,S/AS01E or RTS,S/AS02D at the other. For the other schedules at both study sites, they received RTS,S/AS01E or RTS,S/
AS02D. The primary outcome measure was the occurrence of serious adverse events until 10 months post dose 1.
Results: The number of serious adverse events reported across groups was balanced. One child had a simple febrile
convulsion, which evolved favourably without sequelae, considered to be related to RTS,S/AS01E vaccination. Low grade
reactions occurred slightly more frequently in recipients of RTS,S/AS than rabies vaccines; grade 3 reactions were infrequent.
Less local reactogenicity occurred with RTS,S/AS01E than RTS,S/AS02D. Both candidate vaccines were highly immunogenic
for anti-circumsporozoite and anti-Hepatitis B Virus surface antigen antibodies. Recipients of RTS,S/AS01E compared to
RTS,S/AS02D had higher peak anti-circumsporozoite antibody responses for all 3 schedules. Three dose schedules were
more immunogenic than 2 dose schedules. Area under the curve analyses for anti-circumsporozoite antibodies were
comparable between the 0,1,2- and 0,1,7-month RTS,S/AS01E schedules.
Conclusions: Both candidate malaria vaccines were well tolerated. Anti-circumsporozoite responses were greater with
RTS,S/AS01E than RTS,S/AS02D and when 3 rather than 2 doses were given. This study supports the selection of RTS,S/AS01E
and a 3 dose schedule for further development in children and infants.
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Introduction
Plasmodium falciparum malaria is a major cause of human
suffering and represents an important economic burden to sub-
Saharan African countries [1,2]. A safe and effective vaccine that
prevents P. falciparum malaria would be an important addition to
current control methods.
The RTS,S malaria vaccine candidate (GlaxoSmithKline,
Rixensart, Belgium), is formulated with proprietary Adjuvant
Systems which enhance the ability of the vaccine to induce a
strong immune response. The AS02 Adjuvant System contains an
oil-in-water emulsion with monophosphoryl lipid A (MPL) and
QS21, a natural saponin molecule purified from the bark of the
South American tree Quillaja saponaria. The AS01 Adjuvant System
is based on liposomes and contains the same amounts of MPL and
QS21 as AS02. Both preclinical studies and field studies in adults
have suggested that the AS01 formulation is more immunogenic
than the AS02 formulation [3–5].
AS01 and AS02 were initially developed as the adult
formulations AS02A and AS01B (0.5 mL dose). For compatibility
with standard auto-disable Expanded Program on Immunization
(EPI) syringes, a 0.5 mL variant of the paediatric 0.25 mL dose of
RTS,S/AS02A (RTS,S/AS02D) and of RTS,S/AS01B (RTS,S/
AS01E) were developed.
A large study with the paediatric dose (0.25 mL) of the adult
formulation RTS,S/AS02A, conducted in Mozambican children
aged 1–4 years, demonstrated the vaccine to have an acceptable
safety profile and to be efficacious against clinical malaria (vaccine
efficacy of 35%) and severe malaria disease (vaccine efficacy of 49%)
over a period of 18 months [6]. Subsequently, non-inferiority of the
RTS,S/AS02D formulation compared to a paediatric dose of
RTS,S/AS02A was demonstrated with respect to anti-circumspor-
ozoite (CS) and anti-Hepatitis B Virus surface antigen (HBs)
antibodies in children aged 3 to 5 years from Mozambique [7]. Both
vaccines were shown to have a similar safety profile. More recently,
a similar safety profile of RTS,S/AS02D and RTS,S/AS01E was
demonstrated in children aged 18 months to 4 years in Gabon [8]; a
trend towards better anti-CS and anti-HBs responses with RTS,
S/AS01E was observed. Following administration of RTS,S/AS02D
at 8, 12 and 16 weeks of age to infants in Tanzania, RTS,S/AS02D
had a promising safety profile, met pre-specified non-inferiority
seroconversion rates for co-administered EPI antigens, and reduced
the incidence of malaria infection (vaccine efficacy 65% over 6
months) [9]. In children aged 5 to 17 months in Kenya and
Tanzania, proof-of-concept of the RTS,S/AS01E candidate vaccine
was recently demonstrated in a trial in which vaccine efficacy
against malaria disease was 53%, over an average follow up period
of 8 months [10].
The trial reported here is one of several age de-escalation,
Adjuvant System and schedule selection steps undertaken prior to
the conduct of a phase 3 RTS,S trial. The schedules under
investigation were selected on the basis that they can be integrated
into the existing EPI vaccination programme. Two or three
vaccine doses one month apart (0,1- and 0,1,2-month schedule)
could be administered together with two or three doses of DTP
respectively, while a third delayed dose could be administered
together with measles and yellow fever vaccines at 9 months of age
(0,1,7-month schedule).
Methods
The protocol for this trial [http://clinicaltrials.gov/:
NCT00360230] and supporting CONSORT checklist are avail-
able as supporting information; see Checklist S1 and Protocol S1.
Participants
The trial was conducted at two study centres in Ghana: a
collaboration between the Kumasi Centre for Collaborative
Research (KCCR), Kumasi and the School of Medical Sciences
(SMS), Kwame Nkrumah University of Science and Technology
(KNUST), Kumasi hosted at the Agogo Presbyterian Hospital and
the Kintampo Health Research Centre (KHRC), Ghana Health
Service, Ministry of Health, Kintampo.
The two centers are about 200 km away from each other. The
recruitment area for the KCCR/SMS center was the Agogo town,
while a more rural population was recruited at KHRC. Literacy
rates are similar in both populations. The main activity is farming.
The main population groups around KHRC comprise people from
the Bono and Mo tribes and there is a large population from
northern Ghana that have permanently migrated into Kintampo
District. The majority of the population around KCCR/SMS is
Akan with a small group of migrants from the north of the country.
The study occurred at the same time in the two sites. Although data
for health indicators such as HIV prevalence and malaria
transmission were not collected as part of the study, the climate
and basic health indicators are fairly similar with HIV rates under
4% in both areas. Malaria transmission intensity is intense,
perennial (269 infectious bites/person/year and a prevalence of
malaria parasitaemia among children less than 5 years of about 50%
throughout the whole year in Kintampo in 2004) (Owusu-Agyei S.,
personal communication). Impregnated bednets were distributed at
screening to potential study participants, regardless of whether
children were then enrolled in the trial.
The protocol was approved by the Food and Drugs Board,
Ghana; the Ghana Health Service Ethical Review Committee,
Accra, Ghana; the KHRC Institutional Ethics Committee, the
KHRC Scientific Review Committee; the Committee on Human
Research Protection and Ethics, SMS, KNUST, Kumasi, Ghana;
the London School of Hygiene and Tropical Medicine (LSHTM)
ethics committee, London, UK and the Western Institutional
Review Board, Washington, USA. The trial was undertaken
according to the International Conference on Harmonization,
Good Clinical Practice guidelines and was monitored by
GlaxoSmithKline (GSK) Biologicals. The study was overseen by
a formally constituted Data Safety Monitoring Board (DSMB)
operating under a charter. The DSMB reviewed safety data from a
RTS,S/AS trial in older children [8] prior to authorising the start
of this study, and from a subset of children post dose 1 and post
dose 2, prior to progression to the next vaccination dose within this
trial. A Local Safety Monitor was designated at each site whose
overall role was to support the clinical investigator and to act as a
link between the investigator and the DSMB.
At the KCCR/SMS a register of potentially eligible subjects was
made from children attending the immunisation clinics in the town
of Agogo. KHRC has a Health and Demographic Surveillance
System (KHDSS) in place that registers births, deaths and
migrations to and from the area. The KHDSS was used to
compile a list of potentially eligible children from an electronic
database held at KHRC. In both study sites information was
distributed to parents/legally accepted representatives of potential
participants through meetings organized in the community,
followed by several steps of family and individual based
information sessions, with supporting information material.
Reinforcement and checking of understanding was done with
the support of pre-established documents addressing frequently
asked questions. The whole process happened in the potential
participant’s own language, in the presence of an impartial literate
member of the potential participant’s community if parents/legally
accepted representatives could not read or write.
RTS,S/AS in Ghanaian Children
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To qualify for enrolment children had to be free of obvious
health problems as established by medical history, clinical
examination and laboratory blood markers for safety at screening.
Procedures and interventions (Table 1)
Access of the study population to general clinical care according
to national recommendations was facilitated, in collaboration with
the government services. Hospital services were open for care on a
continuous basis. Access to care was facilitated through the
reimbursement of transport to the hospital and direct or phone
access to field based study staff for the organisation of transport if
needed. Malaria episodes were treated as recommended by the
Ministry of Health of Ghana with oral artesunate and amodia-
quine and IV or IM quinine if hospital admission was needed.
Both in Kintampo and Agogo, study vaccination sessions were
organised in specially dedicated rooms with separated space for
vaccine preparation and administration, located in the vicinity of
standard EPI clinics, the hospital and research center. Recipients of
candidate vaccine were administered lyophilised RTS,S reconsti-
tuted with 0.5 mL of either AS02D or AS01E Adjuvant Systems.
Both candidate and control vaccines were administered intramus-
cularly into the deltoid muscle of the left arm on a 0,1-, 0,1,2- or
0,1,7-month schedule. In KHRC, children on the 0,1,2-month
schedule received rabies vaccine as a control (RabipurH; Chiron
Behring GmbH). In the KCCR/SMS, children on the 0,1,2-month
schedule, received the RTS,S/AS02D experimental vaccine as an
active comparator. Randomisation to each of the other study groups
was balanced between the two study sites. Vaccinees were observed
for 60 minutes following each vaccination.
Volunteers were followed daily for the solicited adverse events
(AEs) of pain, swelling, fever (defined as an axillary temperature
$37.5uC), drowsiness, loss of appetite and irritability/fussiness for
a total of 7 days following each vaccination. Unsolicited non-
serious AEs were collected for 30 days following each dose. Serious
AEs (SAEs) were recorded throughout the study period. Blood
draws for safety evaluation and measurement of humoral
responses were taken at scheduled time points during the study
(see Table 1).
Objectives
The study was a phase II, controlled, randomised, partially-
blinded study of 19 months duration of the safety and im-
munogenicity of two candidate malaria vaccine formulations,
RTS,S/AS02D and RTS,S/AS01E, when given according to three
different immunisation schedules in 5–17 month old children in
Ghana.
Endpoints: safety
The primary safety outcome measure was the occurrence of
SAEs from the time of first vaccination until 10 months post Dose
1. A SAE was defined per protocol as any untoward medical
occurrence that was fatal, life-threatening, required hospitalisa-
tion, led to disability or incapacity, or was judged by investigator’s
as being medically important enough to be reported as serious. In
order to maximize data capture about seizures, all seizures
occurring within 30 days of vaccination had to be reported as
SAEs. Data on seizures occurring within 7 days post vaccination
were collected in a standard way according to Brighton
collaboration guidelines [11]. Secondary safety endpoints included
the occurrence of unsolicited AEs after each vaccination over a 30
day follow-up period, solicited local (pain, swelling) and general
(measured fever, irritability/fussiness, drowsiness, loss of appetite)
reactions over a 7 day period (day of vaccination and 6 subsequent
days) following each vaccination. Grade 3 general reactions were
defined as: fever, an axillary temperature $39.0uC; irritability/
fussiness, crying that could not be comforted/prevented normal
Table 1. Outline of study design.
Month
-1
Month
0
Days
0+6
Month
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month
7
Month
8
Month
9
Month
10
Month
19
Schedule: 0,1-month
Vaccination X X
Serology CS X X X X X
HBs X X X
Safety BS X X X X X X
Schedule: 0,1,2-month
Vaccination X X X
Serology CS X X X X X
HBs X X X
Safety BS X X X X X X
Schedule: 0,1,7-month
Vaccination X X X
Serology CS X X X X X
HBs X X X
Safety BS X X X X X X
Double blind (observer blind) phase: screening (Month -1, Month 0, Days 0 and 6) and primary study (Months 1–10).
Single blind phase: extended follow up: Month 19.
Schedule 0,1-month: RTS,S/AS01E (N = 90*), RTS,S/AS02D (N= 90*).
Schedule 0,1,2-month : RTS,S/AS01E (N = 90*), RTS,S/AS02D (N= 45**), Rabies (N = 45***).
Schedule 0,1,7-month: RTS,S/AS01E (N = 90*), RTS,S/AS02D (N= 90*).
FU = follow-up; BS = blood sample; *KHRC= 45, KCCR/SMS=45; **KCCR/SMS only; ***KHRC only.
doi:10.1371/journal.pone.0007302.t001
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activity; drowsiness that prevented normal activity; loss of appetite,
not eating at all. Grade 3 solicited local injection site reactions
were defined as: pain, cried when limb moved/spontaneously
painful; swelling, exceeding 20 mm in diameter. Safety laboratory
blood assessments for haematological (haemoglobin, white blood
cells [WBC], platelets), renal (creatinine), and hepatic (alanine
aminotransferase [ALT]) parameters were conducted at specific
time points during the study (see Table 1). Tertiary endpoints
included an assessment of SAEs up to 19 months post Dose 1.
For each AE/SAE, investigators had to assess whether (yes or
no) there was a reasonable possibility that the AE may have been
caused by the investigational product, using clinical judgment and
taking into account the natural history of the underlying diseases,
concomitant therapy, other risk factors, the temporal relationship
of the event to the investigational product and available
information on experimental or marketed products. All solicited
injection site reactions were considered causally related to
vaccination.
Endpoints: immunogenicity
Anti-CS and anti-HBs antibodies were assessed prior to
vaccination and on several occasions until 19 months post dose
1 (see Table 1). Antibody levels against the CS protein tandem
repeat epitope were measured by a standard, validated ELISA
using theR32LR antigen that contains the sequence
[NVDP(NANP)15]2LR [7]. Antibody responses against the HBs
were quantified by a GSK validated sandwich ELISA. Briefly, 96-
well microplates were coated with native HBs and after washing
and blocking steps, dilutions of serum samples, controls and
standard were added to the plate. After washing, a recombinant
horseradish peroxidase conjugated HBs was added as secondary
reagent. After a final washing step and a colorimetric reaction with
3,39,5,59 tetramethylbenzidine stopped by addition of sulphuric
acid, the plates were read in an ELISA reader. Titres were
calculated using the reference standard curve with a 4 parameter
logistic fitting algorithm and expressed in mIU/mL. The cut-off
was set at 3.3 mIU/mL.
Sample size
For any comparison between two study groups, the study had
80 percent power to detect an approximately 3 fold increase of
events, for an event occurring at a frequency of ten percent in the
comparator group, by Fisher exact test (alpha 5%).
For the secondary immunogenicity endpoints, anti-CS titres, a
sample size of 75 evaluable subjects per group would have 90%
power to demonstrate equivalence of the two vaccine regimens
under comparison (i.e. x versus y, 95% CI of the GMT ratio x/y is
within the range 0.33 to 3.0) at any time point assuming a log
standard deviation of 0.9 in both groups, alpha = 0.025.
Randomisation and blinding
Subjects were allocated sequentially to treatment numbers in
the order that they presented for vaccination. Treatment numbers
were assigned to vaccines with a randomisation list generated
using a standard SASH (Statistical Analysis System) programme.
Subjects were allocated randomly (1:1:1:1:1:1) to one of six study
groups at each study site, each defining which vaccine should be
given and by which schedule (0,1-, 0,1,2- or 0,1,7-months). For the
0,1,2-month schedule this meant RTS,S/AS01E or rabies vaccine
at KHRC and RTS,S/AS01E or RTS,S/AS02D at KCCR/SMS.
For the other schedules at both study sites, this meant either
RTS,S/AS01E or RTS,S/AS02D.
During the primary phase of the study, i.e. up to month 10, the
study was partially blinded, whereby investigators involved in
endpoint evaluation and parents/guardians were blinded to the
vaccine administered, but not to the schedule. The vaccine
administration occurred in a separate room in the presence of a
vaccination team that was not involved in any other part in the
study, as described in detailed standard procedures. From months
10 to 19, during the extended follow-up period, the study was
single-blind as parents/guardians remained blind to the study
vaccine.
Statistical methods
Analysis was carried out according to a DSMB approved report
and analysis plan established before unblinding of trial data.
Safety. The proportion of subjects with a SAE, classified by
the MedDRA preferred term level, reported from study start until
study conclusion was tabulated with exact 95% confidence interval
(CI). The percentage of subjects with at least one solicited local
and general AE reported within 7 days post each vaccination was
also tabulated, with exact 95% CI. The proportion of subjects who
reported an unsolicited AE within 30 days post each vaccination,
classified by the MedDRA preferred term level, was tabulated with
exact 95% CI. Similar tables were generated for Grade 3 solicited
and unsolicited AEs and for the relationship of the event to
vaccination; per protocol, all solicited local AEs were considered to
be related to vaccination. Biochemistry (ALT and creatinine) and
haematology (haemoglobin, WBC, platelets) values outside of the
reference ranges were described up to 19 months post Dose 1;
frequency distribution of results by predefined toxicity grades were
tabulated by group.
Immunogenicity. The percentage of subjects seropositive for
anti-CS antibody (anti-CS antibody titres $0.5 EU/mL) with
95% CI was determined at each blood sampling time point
(Table 1). Antibody titres were summarised by GMT with 95%
CI. The area under the curve (AUC) of anti-CS responses over
time was estimated over the vaccination period to month 7
(AUC7) and over the whole study duration to month 19 (AUC19),
by trapezoidal rule using the consecutive blood samples. Month 2
data from the 0,1-month schedule was used to estimate the AUC
for the 0,1,7-month schedule. Standardised AUC (sAUC),
calculated by dividing AUC by follow-up time, was also calculated.
The seroprotective level for anti-HBs antibody was$10 mIU/mL.
The percentage of subjects with seroprotective levels of anti-HBs with
95% CI was determined at each blood sampling time point (Table 1).
Antibody titres were summarised by GMT with 95% CI at each blood
sampling time point.
Results
Participant flow
In total, 756 subjects were screened of whom 540 were enrolled
into the study and evaluated for safety; 90 in each of the RTS,S/
AS02D (0,1- and 0,1,7-month) and RTS,S/AS01E (0,1-, 0,1,2- and
0,1,7-month) groups and 45 in each of the RTS,S/AS02D (0,1,2-
month) and rabies vaccine groups (Figure 1). 531 subjects received
all vaccine doses as scheduled and 521 were evaluable for the ATP
cohort for immunogenicity. Twenty-five subjects (4.6%) were
prematurely withdrawn from the study, predominantly due to
migration from the study area (15 subjects).
The first subject was enrolled in the study on 30 August 2006
and the last study visit was made on 30 May 2008.
Baseline data
For the total vaccinated cohort and the ATP cohort for
immunogenicity the mean age at study entry was 10.7 months
RTS,S/AS in Ghanaian Children
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(standard deviation [SD] 3.5). Each group was balanced for
gender and age, overall and by study center (Table 2).
Safety
Serious adverse events. 11.1% [5.5–19.5] and 20.0% [12.3–
29.8] of the subjects in the RTS,S/AS02D (0,1-month) group,
21.1% [13.2–31.0] and 25.6% [16.9–35.8] in the RTS,S/AS01E
(0,1-month) group, 11.1% [3.7–24.1] and 24.4% [12.9–39.5] in the
RTS,S/AS02D (0,1,2-month) group, 14.4% [7.9–23.4] and 24.4%
[16.0–34.6] in the RTS,S/AS01E (0,1,2-month) group, 18.9%
[11.4–28.5] and 26.7% [17.9–37.0] in the RTS,S/AS02D (0,1,
7-month) group, 15.6% [8.8–24.7] and 18.9% [11.4–28.5] in the
RTS,S/AS01E (0,1,7-month) group, and 13.3% [6.1–26.8] and
15.6% [6.5–29.5] in the Rabies (0,1,2-month) group reported at
least one SAE from day of first vaccination to Month 10 (primary
endpoint) and Month 19, respectively. No apparent imbalance
between study groups in the occurrence of SAEs was observed,
which was also true for the entire study duration, to Month 19 (not
shown).
Four subjects died during the trial; one child from the RTS,S/
AS01E 0,1,7-month schedule group died at home 7 days after
having received the second experimental vaccine dose. A diagnosis
of bronchopneumonia was made by verbal autopsy. One child
from the rabies vaccine group died in hospital from severe malaria
with severe anaemia and sepsis 7 months after the last vaccine
dose. One child from the RTS,S/AS01E 0,1-month schedule
group died in hospital of cerebral malaria 17 months after the last
vaccine dose. Another child died in hospital of severe malaria,
severe anaemia and convulsions, 18 months after enrolment. He
was due to receive RTS,S/AS01E (0,1,7-month schedule) but the
first vaccination attempt failed, there was spillage of the attributed
vaccine dose, and he received only a negligible amount of vaccine.
After this failed attempt, he was not further vaccinated. None of
the fatal SAEs were considered to be related to vaccination.
One SAE was considered to be related to vaccination: an 18
month old boy experienced a simple febrile seizure 14 hours after
dose 3 of RTS,S/AS01E at home. Earlier on the same day, fever
had been recorded as part of the routine reactogenicity
monitoring. A few hours after the episode of convulsion he was
seen at the district hospital, and found to be well. Physical
examination and laboratory assessment did not show any evidence
of infectious disease. He was treated with paracetamol only. He
was kept for observation for 2 days and went home thereafter.
Two children in the study were diagnosed with intussusception.
The first case was a 14 month old boy who presented on the day
following the first RTS,S/AS01E vaccination (0,1-month schedule
group) with mucoid bloody diarrhoea, vomiting and fever, and
was treated with oral antibiotics. Five days later he returned with a
mass in his epigastrium. The second case was a 7 month old boy
who presented fifteen days after first RTS,S/AS02D vaccination
Figure 1. CONSORT diagram for study participants.
doi:10.1371/journal.pone.0007302.g001
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(0,1,7-month schedule group) with a 1 day history of bloody
mucoid stool, abdominal pain and a mass in the epigastrium. Both
children were referred to the tertiary level university hospital
where the diagnosis of intussusception was confirmed and treated
surgically. Both children recovered fully. On the basis of the
absence of obvious pathogenic explanation for these vaccine
components being causative of intussusceptions, as well as the fact
that they occurred at different time intervals after vaccination and
following vaccination with different vaccine formulations, the
investigators considered the intussusceptions not to be related to
vaccination. The DSMB concurred with this assessment.
Non-serious adverse events and reactogenicity. For each
RTS,S vaccine formulation, reactogenicity seen after the first two
doses in the three vaccine schedule groups was similar. Therefore
the description of reactogenicity focuses on the data from the
0,1,2- and 0,1,7-month schedules and data from the 0,1-month
schedule groups is not presented here.
Pain at the injection site was the most frequently reported
solicited local symptom. It was reported with a higher frequency
in the RTS,S/AS02D compared to the RTS,S/AS01E group
(overall/dose: 0,1,2-month schedule, 43.6% vs 29.6% [rabies
20.1%]); 0,1,7-month schedule, 53.2% vs 44.1%, respectively).
Although Grade 3 pain occurred with a low incidence, there was a
trend towards a higher frequency of Grade 3 pain in the RTS,
S/AS02D compared to the RTS,S/AS01E group (Figure 2).
A similar pattern was observed for swelling (overall/dose: 0,1,
2-month, RTS,S/AS02D 35.3% vs RTS,S/AS01E 12.6% [rabies
2.2%]; 0,1,7-month, RTS,S/AS02D 18.4% vs RTS,S/AS01E
14.1%). Grade 3 swelling events were infrequent (Figure 2).
Fever was the most frequently reported solicited general symptom,
occurring with a similar incidence in both the RTS,S/AS02D and
RTS,S/AS01E vaccine groups and in both the 0,1,2-month (overall/
dose: 39.1% vs 35.9%, respectively [rabies 11.2%]) and the 0,1,
7-month (47.9% vs 46.8%, respectively) schedules (Figure 2). Grade 3
fever events were reported in the 0,1,2-month group following 0.8%
and 1.9% of RTS,S/AS02D and RTS,S/AS01E doses respectively
(rabies 1.5%), and in the 0,1,7-month group following 5.6% and
2.7% of RTS,S/AS02D and RTS,S/AS01E doses, respectively.
Unsolicited non-serious AEs were reported by a similar proportion
of subjects who received RTS,S/AS02D or RTS,S/AS01E in the
0,1,2-month (53.4% vs 57.4% [rabies 59.7%]) and in the 0,1,7-month
(93.3% vs 94.4%) groups. There was no trend in non-serious AEs
Graded 3 for intensity across groups (0,1,2-month, 2.2% RTS,
S/AS02D vs 7.8% RTS,S/AS01E [rabies 4.4%]; 0,1,7-month, 10.0%
RTS,S/AS02D vs 7.8% RTS,S/AS01E). There were no non-serious
AEs estimated by the investigators to be related to vaccination.
Haematology (haemoglobin, WBC, platelets) and biochemistry
(ALT, creatinine) values outside the normal range were infrequent.
Three subjects had values graded 3. One subject in the RTS,
S/AS02D (0,1,7-month) group had elevated ALT at month 7
(416 U/mL). The child was found to be well, followed up clinically
and the ALT level was normal at the next visit. One subject in the
RTS,S/AS02D (0,1,7-month) group had elevated ALT at month 7
(353 U/mL). He had a concomitant upper respiratory tract
infection and was otherwise well. He was followed up clinically
and the ALT level was normal at the next visit. One subject in the
RTS,S/AS01E (0,1,7-month) group had raised creatinine at
month 8 (225 mg/dL). He was found to be well clinically, and
at the next visit the creatinine concentration had reduced
(67.1 mg/dL).
Immunogenicity
All subjects were seropositive for anti-CS antibodies following 2
doses of either RTS,S/AS01E or RTS,S/AS02D; low, background
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levels of anti-CS antibodies were found in rabies-vaccinated
subjects.
In general, the levels of antibody responses in Kintampo were
slightly higher than those in Agogo. For example, in the 0,1,7-month
schedule groups, peak (month 8) anti-CS GMT following vaccina-
tion with RTS,S/AS02D was 230 (95% CI 171, 309) in Agogo and
316 (95% CI 228, 437) in Kintampo, and following vaccination with
RTS,S/AS01E was 363 (95% CI 274, 481) in Agogo and 383 (95%
CI 301, 488) in Kintampo (other data not shown). This trend was
also observed for anti-hepatitis B antibodies (data not shown). The
general conclusions from analysis of site-specific results (data not
shown) were similar to those following review of pooled data from
the two research centres as presented here.
Within each vaccination schedule group, the RTS,S/AS01E
formulation consistently yielded higher peak anti-CS responses as
compared to RTS,S/AS02D. The highest anti-CS GMTs were
seen with the 0,1,2-month schedule at month 3 (632 EU/mL
[95% CI 554, 720]). With the same schedule, the RTS,S/AS02D
formulation induced anti-CS GMTs of 367 EU/mL (95% CI 293,
459). With the 0,1,7-month schedule at month 8, anti-CS GMTs
were 373 EU/mL (95% CI 311, 447) for the RTS,S/AS01E
formulation and 272 EU/mL (95% CI 219, 339) for the RTS,S/
AS02D formulation. With the 0,1-month schedule at month 2,
anti-CS GMTs were 483 EU/mL (95% CI 395, 591) for the
RTS,S/AS01E formulation and 318 EU/mL (95% CI 269, 377)
for the RTS,S/AS02D formulation.
At month 7, subjects having received two vaccine doses (i.e. the
0,1-month schedule) had lower anti-CS GMTs (AS02D: 35 EU/mL
[95% CI: 26, 46]; AS01E: 53 EU/mL [95% CI: 41, 68]) than
subjects having received 3 vaccine doses (0,1,2-month schedule)
(AS02D: 78 EU/mL [95% CI: 58, 106]; AS01E: 162 EU/mL [95%
CI: 134, 196]). This trend was also observed at month 19.
At month 19, similar anti-CS levels were found in both RTS,
S/AS01E schedule groups (0,1,7-month schedule 51 EU/mL
[95% CI: 40, 66], 0,1,2-month schedule 46 EU/mL [95% CI:
37, 57]). In the RTS,S/AS02D groups, the 0,1,7-month schedule
induced higher month 19 anti-CS titres as compared to the 0,1,
2-month schedule (44 EU/mL [95% CI: 33, 58] vs 20 EU/mL
[95%CI: 14, 29] respectively) (Figure 3).
For all schedules, AUC was consistently higher for the RTS,
S/AS01E groups compared to the RTS,S/AS02D groups (Table 3).
For the RTS,S/AS01E formulation, anti-CS sAUC19 over the whole
study duration were comparable for the 0,1,2- and 0,1,7-month
schedules and higher than for the 0,1-month schedule; the same trend,
but less pronounced was observed for the RTS,S/AS02D formulation.
Anti-CS responses during the vaccination period (sAUC7) were high
for all study groups with an apparent trend towards the highest values
with the 0,1,2-month schedule in the RTS,S/AS01E group.
Figure 2. Percentage of solicited events post dose 1, 2 and 3 (Total Vaccinated Cohort). Yellow=RTS,S/AS02D; Green=RTS,S/AS01E;
Grey = Rabies vaccine; Orange=Grade 3 Bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0007302.g002
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All the subjects in this study had previously received hepatitis B
vaccination as part of their national EPI, with at least 84% of
subjects having seroprotective levels of anti-HBs antibodies at
screening. All children who received at least 2 RTS,S vaccine
doses had seroprotective levels of anti-HBs antibodies, except one
subject in the RTS,S/AS02D 0,1-month schedule group. Sero-
Figure 3. Anti-CS GMTs (EU/mL) responses over time (0,1,2- and 0,1,7-month schedules; ATP Cohort for Immunogenicity). Note :
There was no month 2 blood sample in the 0,1,7-month schedule group. Month 2 data from the 0,1-month schedule group was used instead.
doi:10.1371/journal.pone.0007302.g003
Table 3. GMTs and sAUC for anti-CS antibodies and GMTs for anti-HBs antibodies (ATP Cohort for Immunogenicity).
Schedule 0,1-month 0,1,2-month 0,1,7-month
RTS,S/AS02D RTS,S/AS01E RTS,S/AS02D RTS,S/AS01E Rabies RTS,S/AS02D RTS,S/AS01E
Anti-CS (EU/mL); GMTS [95% CI]
SCR 0.3 [0.3, 0.4] 0.3 [0.3, 0.4] 0.3 [0.2, 0.3] 0.3 [0.3, 0.4] 0.3 [0.3, 0.4] 0.3 [0.3, 0.3] 0.3 [0.3, 0.4]
M2 318 [269, 377] 483 [395, 591]
M3 - - 367 [293, 459] 632 [554, 720] 0.4 [0.3, 0.6] - -
M7 35 [26, 46] 53 [41, 68] 78 [58, 106] 162 [134, 196] 0.3 [0.3, 0.4] 26 [20, 34] 51 [40, 64]
M8 - - - - - 272 [219, 339] 373 [311, 447]
M10 20 [15, 27] 32 [23, 40] 43 [32, 60] 102 [83, 125] 0.3 [0.3, 0.4] 120 [92, 156] 167 [140, 198]
M19 10 [7,14] 15 [11,21] 20 [14, 29] 46 [37, 57] 0.5 [0.3, 0.7] 44 [33, 58] 51 [40, 66]
Anti-CS sAUC; Gmean [95% CI]
sAUC7 181 [151, 218] 269 [218, 332] 225 [182, 279] 371 [324, 426] - 166* [139, 198] 249* [204, 302]
sAUC19 83 [69, 101] 124 [101, 153] 113 [90, 143] 200 [173, 232] - 141 [116, 173] 203 [172, 240]
Anti-HBs (mIU/mL); GMTS [95% CI]
SCR 101 [68, 149] 108 [74, 158] 109 [61, 195] 82 [61, 111] 108 [64, 183] 88 [61, 128] 90 [61, 133]
M2 17043 [10467, 27751] 15107 [9508, 24001]
M3 30000 [18799,
47874]
34935 [25178,
48474]
122 [63, 235]
M8 96754 [72062, 129908] 103225 [83035, 128324]
M19 3510 [2398, 5137] 4478 [3155, 6357] 5112 [3350, 7803] 7106 [5161, 9784] 114 [58, 227] 17191 [12529, 23589] 13386 [9661, 18548]
SCR= screening visit; sAUC 7/19 = standardised area under the curve over the vaccination period to Month 7/Month 19.
*sAUC7 here represents a period during which only the first two vaccine doses were given, as for the 0,1-month schedule.
doi:10.1371/journal.pone.0007302.t003
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positivity rates in the rabies group were 84%, illustrating a
persistence of the response induced by the prior hepatitis B EPI
vaccination.
Very high levels of anti-HBs GMTs were seen in subjects
vaccinated with RTS,S vaccines; no significant difference was seen
between RTS,S/AS01E and RTS,S/AS02D formulations within
vaccine schedules (Table 3). One month post last dose and at
month 19, the 0,1,7-month schedule generated the highest anti-
HBs GMTs.
Discussion
The development of a safe, effective malaria vaccine accessible
to those who need it most is a critical global public health priority
[12]. Evidence of immunogenicity, efficacy and a favourable safety
profile of the RTS,S/AS02 candidate malaria vaccine has been
demonstrated in adults [13–16] and subsequently in children and
infants [7,17–21].
Pre-clinical data suggested that the liposomal Adjuvant System
formulation RTS,S/AS01 induces stronger immune responses as
compared to RTS,S/AS02 [3]. In healthy human adults RTS,S/
AS01, as compared to RTS,S/AS02, induced higher levels of anti-
CS antibodies and CS-specific CD4 positive helper T cells
expressing markers of activation and/or effector cytokines, and a
trend towards higher protection against infection following
experimental sporozoite challenge [4]. The good safety profile
and high immunogenicity of the RTS,S/AS01 formulation was
confirmed in malaria-exposed adults in Kenya [5].
Recently completed trials have compared the paediatric
formulations of the candidate vaccines RTS,S/AS02D and
RTS,S/AS01E in children aged 18 months to 4 years from Gabon
[8], assessed RTS,S/AS02D when coadministered with EPI
antigens in infants from Tanzania [9] and established proof-of-
concept of RTS,S/AS01E in children aged 5 to 17 months from
Kenya and Tanzania [10]. The trial reported here is the next in a
series of age de-escalation steps towards the EPI age range,
contributing to adjuvant and schedule selection. This study is the
first comparative assessment of both candidate vaccines in young
children aged 5 to 17 months and assessed three different
vaccination schedules (0,1-, 0,1,2- and 0,1,7-months).
Overall, both the RTS,S/AS02D and RTS,S/AS01E formula-
tions were shown to have a good safety profile and were well
tolerated. One subject experienced an episode of simple febrile
seizure considered to be related to vaccination following the third
dose of RTS,S/AS01E at month 7. In the RTS,S program to date
5315 doses of RTS,S/AS02 and 3149 doses of RTS,S/AS01 have
been administered to 1864 and 1145 children under 6 years of age,
respectively. Out of these one other case of simple febrile seizure
related to vaccination has occurred [10]. Post vaccination febrile
seizures are a well described complication of vaccine-related fever
[11]. In the great majority of the cases, such as in these that have
occurred in the RTS,S programme, it is benign, and resolves
without sequelae. Two cases of intussusception (one in a RTS,S/
AS02D vaccinated child, one in a RTS,S/AS01E vaccinated child)
were reported in this study. Intussusception is a condition known
to occur in this age group, including in Ghana, although precise
incidence rates are unknown [22]. No other case of intussusception
has been described in the RTS,S program to date.
The analysis of reactogenicity data indicated that although
recipients of the malaria vaccine candidates reported more local
and general symptoms than recipients of the rabies vaccine, grade
3 reactions were infrequent. A trend towards less local reactoge-
nicity in recipients of the RTS,S/AS01E vaccine formulation as
compared to RTS,S/AS02D recipients was found.
In a previous study in children aged 18 months to 4 years from
Gabon, both candidate vaccines were shown to have a good safety
profile and to be well tolerated [8]. In the study in Gabon, an
increase in solicited local symptoms of pain and swelling at the
injection site with subsequent doses of either vaccine was observed;
this was not seen in this study. More recently, the RTS,S/AS02D
formulation coadministered to infants with other routinely
delivered EPI immunisations, and RTS,S/AS01E administered
to children aged 5 to 17 months from Kenya and Tanzania, had
favourable safety profiles [9,10].
Both candidate vaccines were highly immunogenic for anti-CS
antibodies. Following two doses of either RTS,S/AS01E or RTS,S/
AS02D, all subjects had seropositive levels of anti-CS antibodies.
The peak anti-CS titres were higher than those observed in previous
studies in children with RTS,S candidate vaccines [6,7,8,20,21].
This may be related to the fact that in this study all children had
been previously immunised against hepatitis B. Indeed, it has
previously been observed that prior HBV vaccination appears to
promote the immune response to both HBs and CS antigen
components of RTS,S/AS02 and RTS,S/AS01 [8]. Such high anti-
CS and –HBs titres were also observed following administration of
RTS,S/AS01E to young children previously vaccinated with
hepatitis B vaccine in another study [10].
The antibody response to the CS protein is believed to be an
important component or marker of protective immunity although,
to date, no protective threshold of CS antibody response has been
determined. Future studies with the RTS,S candidate vaccines will
investigate the priming effect of a neonatal dose of hepatitis B
vaccine on the evolution of CS titres induced by the malaria
vaccine.
Recipients of RTS,S/AS01E consistently had higher peak anti-
CS responses compared to recipients of RTS,S/AS02D, irrespec-
tive of vaccination schedule. Although responses in subjects who
received just 2 doses (i.e. 0,1-month schedule) were high, the
decline from peak GMTs was more important than in subjects on
a 3 dose regimen. Anti-CS titres were higher at month 10 in
children on the 0,1,7-month schedule as compared to the 0,1,2-
month schedule, for both RTS,S vaccine groups. At month 19 this
was still apparent in children vaccinated with RTS,S/AS02D but
in children vaccinated with RTS,S/AS01E they were similar.
In an attempt to estimate antibody response over the whole
timeframe of the study, while acknowledging the variation in the
responses over time, AUCs standardised over time were evaluated.
The evaluation over the whole study duration (AUC19) showed
that mean responses with the RTS,S/AS01E formulation were
similar for both the 0,1,2- and 0,1,7-month schedules, which were
higher than those seen with the two doses schedule. Although the
anti-CS response following two doses was high, the peak, AUC7
and AUC19 in the 0,1,2-month schedules were higher. A two
doses schedule is therefore probably not optimal.
Peak responses for anti-CS GMTs were observed in the 0,1,2-
month schedules, which was an unexpected result as, in line with
licensed Hepatitis B vaccine schedules, trials with a hepatitis B
vaccine have shown that increasing the interval between the
second and third dose enhances humoral response [23,24].
Indeed, the highest peak responses for anti-HBs GMTs were
observed in the 0,1,7-month schedules as compared to the 0,1,2-
month schedule when considering the peak (one month post last
dose) responses. It is not clear why the delayed third dose is
associated with a marked increase in HBs response but not CS
response and will need to be investigated further in delayed
booster studies.
This study confirmed the previously demonstrated high
immunogenicity of RTS,S based vaccines for anti-HBs antibodies,
RTS,S/AS in Ghanaian Children
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and that this is true also in subjects primed with hepatitis B
vaccine.
In two similar Ghanaian populations, antibody responses were
high though there was some variability between the two centers.
Slightly higher antibody levels were found in KHRC participants,
as compared to KCCR/SMS participants. Some variability
magnitude of anti CS response between centers has previously
been observed and the precise source of this heterogeneity is
unclear. Future multicenter Phase 3 RTS,S studies will further
characterize heterogeneity in vaccine immunogenicity and efficacy
in different geographical locations.
This trial demonstrated that both formulations of the candidate
malaria vaccines, RTS,S/AS01E and RTS,S/AS02D, were well
tolerated and highly immunogenic for anti-CS and anti-HBs
antibodies in young children aged 5–17 months living in a
malaria-endemic area. RTS,S based vaccines were well tolerated
in children having previously received a full course of anti-HBs
vaccine in infancy as part of EPI. The RTS,S/AS01E formulation
showed a trend towards less local reactogenicity and demonstrated
higher immunogenicity for anti-CS antibodies. The 3 dose
schedules were more immunogenic than 2 dose schedules with
AUC analyses for anti-CS antibody levels and were comparable
between the 0,1,2- and 0,1,7-month RTS,S/AS01E schedules. In
summary, this study supports further evaluation of the RTS,S/
AS01E candidate vaccine with both 0,1,2- and 0,1,7-month
schedules in infants, and when co-administered with standard
EPI antigens.
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